Regional Urology

Shreveport, Louisiana 71106

0 studies enrolling now · 29 studies all time

What they study most

Benign Prostate Hyperplasia, Benign Prostatic Hyperplasia, Enteric Hyperoxaluria, Erectile Dysfunction, Hypogonadism, Hypogonadism, Male, Metastatic Castration Resistant Prostate Cancer, Overactive Bladder, Overactive Bladder Syndrome (OABS), Prostate Cancer, Prostatic Neoplasms, Stress Urinary Incontinence

Studies at this site

• Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters — Recruiting now
• Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer — Completed
• A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder — Stopped early
• Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence — Withdrawn before enrolling
• To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer — Stopped early
• Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence — Withdrawn before enrolling
• Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer — Stopped early
• Vesair Balloon Confirmatory Trial (VECTOR) — Stopped early
• Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria — Stopped early
• Vesair Clinical Trial — Stopped early
• Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) — Stopped early
• Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men — Completed
• Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence — Completed
• Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria — Completed
• Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC) — Completed
• Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence — Completed
• Solace Stress Urinary inContinence Control Efficacy and Safety Study — Completed
• Vesair Continued Access Trial — Completed
• Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) — Status unconfirmed
• SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS) — Completed
• A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy — Completed
• The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer — Completed
• A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer — Completed
• Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy — Completed
• A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer — Completed
• Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors — Completed
• Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer — Completed
• Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer — Completed
• A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer — Completed